Starlight Kunze

Starlight Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for central nervous system (CNS) disorders, with a primary emphasis on glioblastoma multiforme (GBM). As a subsidiary of ClearPoint Neuro, the company leverages advanced navigation and delivery technologies to improve the precision of drug administration to the brain. Their lead program involves the delivery of therapeutic agents directly into the tumor site using MRI-guided systems. Starlight aims to address the significant unmet need in neuro-oncology by combining cutting-edge medical devices with novel pharmacological treatments. The company's approach seeks to enhance patient outcomes through localized and targeted intervention in aggressive brain cancers.